Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... A new vaccine created to fight an illness similar ... livestock and even humans from similar brain infections, researchers ... from becoming infected by the incurable brain disorder known ... the Dec. 21 online edition of the journal ... infectious particles known as prions that go rogue. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Super Saturday, ... Friday this year as the busiest day in the ... retailers, The Grass Station had a steady pre-Christmas stream ... gifts, this past Saturday. , “I definitely intend to ... Robert, a Denver resident who was enjoying The Grass ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... December 22, 2014 TheHardwareCity.com now stocks ... with many useful features. Customers of the large online ... the new gloves delivered to their home or workplace ... hand tools that incorporate heavy duty magnets, which make ... allows workers to store metal parts on the back ...
Breaking Medicine News(10 mins):Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... Society of Corporate Compliance and Ethics and Health ... critical time when the public, government leaders and ... bonus reforms, it appears that there is relatively ... according to a recent survey conducted by the ...
... 28 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... Mr. Hubert Cooleman, Flemish economic representative for the North ... Ren Medical Company ("TDR"), a wholly-owned subsidiary of China ...
... Americans Suffer in Silence ... From Constipation(1): From Connecticut ... -NEW YORK, May 28 While it might not ... comfortable talking about constipation, the results of a new ... topic really is: In fact, while more than ...
... 28 Air Products (NYSE: APD ) ... John E. McGlade will be presenting at the Goldman ... June 4, 2009, at 8:00 a.m. EDT. An audio ... Products, Investor Relations web site at www.airproducts.com/Invest/PresentationSummary.htm . ...
... ESA,s next Earth Explorer, SMOS, has just passed the all-important ... up the mission are in place for launch later this ... to the Plesetsk Cosmodrome in northern Russia. , The Flight ... the mission elements are in order and ready for launch. ...
... 28 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ... and commercialization of proprietary products that address important therapeutic ... Glenn A. Oclassen, President & Chief Executive Officer, is ... Science Conference in New York City on Wednesday, June ...
Cached Medicine News:Health News:Survey Data Reveals Little Connection between Executive Compensation, Employee Bonuses and Business Ethics and Compliance 2Health News:Survey Data Reveals Little Connection between Executive Compensation, Employee Bonuses and Business Ethics and Compliance 3Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 2Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 3Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 2Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 3Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 4Health News:SMOS ready to ship to launch site 2Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 2Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 3
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
(Date:12/22/2014)... Dec. 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) ... vaccine, has been filed and is now open and ... the Department of Health and Human Services (HHS), through ... "We are extremely pleased to have the IND ... represents a significant milestone in our company,s partnership with ...
(Date:12/22/2014)... , Dec. 22, 2014 TWi Biotechnology, ... of Allowance for AC-201, TWi Biotechnology,s lead drug ... China for patent application ... pharmaceutically acceptable salts, active metabolite for treatment of ... methods of treatment using AC-201 for type II ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... leading developer of stereotactic radiosurgery and cancer treatment ... cancer center, which will begin treating patients in ... a partnership between Accelitech, physicians and Swedish Covenant ... will provide state-of-the-art CyberKnife treatment to patients from ...
... ST. LOUIS, Feb. 22, 2012 Express Scripts, Inc. (Nasdaq: ... year net income from continuing operations of $290.4 million and ...  Adjusted earnings per share, as detailed in Table 4 were ... and full year, respectively. "Through our unwavering ...
Cached Medicine Technology:Accelitech to Open the First CyberKnife Cancer Center Within the City of Chicago 2Express Scripts Reports Fourth Quarter Results 2Express Scripts Reports Fourth Quarter Results 3Express Scripts Reports Fourth Quarter Results 4Express Scripts Reports Fourth Quarter Results 5Express Scripts Reports Fourth Quarter Results 6Express Scripts Reports Fourth Quarter Results 7Express Scripts Reports Fourth Quarter Results 8Express Scripts Reports Fourth Quarter Results 9Express Scripts Reports Fourth Quarter Results 10Express Scripts Reports Fourth Quarter Results 11Express Scripts Reports Fourth Quarter Results 12
... inserted into the subclavian or jugular vein ... The Cool Line incorporates two proprietary, ... flowing within a closed-loop design, enabling direct ... The Cool Line combines two important patient ...
...
Designed to minimize emblolic debris in SVGs and carotids...
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
Medicine Products: